Increases in CD4 + T-Cell Count at Antiretroviral Therapy Initiation among HIV-Positive Illicit Drug users during a Treatment-as-Prevention Initiative in Canada
Free accessResearch articleFirst published online July, 2017
Increases in CD4 + T-Cell Count at Antiretroviral Therapy Initiation among HIV-Positive Illicit Drug users during a Treatment-as-Prevention Initiative in Canada
Although treatment-as-prevention (TasP) efforts are a new cornerstone of efforts to respond to the HIV/AIDS pandemic, their effects among people who use drugs (PWUD) have not been fully evaluated. This study characterizes temporal trends in CD4+ T-cell (CD4) count at ART initiation and rates of virological response among HIV-positive PWUD during a TasP initiative.
Methods
We used data on individuals initiating ART within a prospective cohort of PWUD linked to comprehensive clinical records. Using multivariable linear regression, we evaluated the relationship between CD4 count prior to ART initiation and year of initiation and time to HIV-1 RNA viral load <50 copies/ml following initiation using Cox proportional hazards modelling.
Results
Among 355 individuals, CD4 count at initiation rose from 130 to 330 cells/ml from 2005 to 2013. In multivariable regression, initiation year was significantly associated with higher CD4 count (β=29.5 cells per year, 95% CI 21.0, 37.9). Initiating ART at higher CD4 counts was significantly associated with optimal viral response (adjusted hazard ratio =1.13 per 100 cells/ml increase, 95% CI 1.05, 1.22).
Conclusions
Increases in CD4 cell count at initiation over time was associated with superior virological response, consistent with the aims of the TasP initiative.
References
1.
BaeJ.W., GuyerW., GrimmK., AlticeF.L.Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research.AIDS2011; 25: 279–290.
2.
HoggR.S., HeathK., BangsbergD.Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up.AIDS2002; 16: 1051–1058.
3.
WoodE., KerrT., ZhangR.Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users.HIV Med2008; 9: 503–507.
4.
GrigoryanA., HallH.I., DurantT., WeiX.Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996–2004.PLoS One2009; 4: e4445.
5.
Rodríguez-ArenasM.A., JarrinI., del AmoJ.Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain.AIDS Res Hum Retroviruses2006; 22: 715–723.
6.
WalenskyR.P., PaltielA.D., LosinaE.The survival benefits of AIDS treatment in the United States.J Infect Dis2006; 194: 11–19.
7.
KitahataM.M., GangeS.J., AbrahamA.G.Effect of early versus deferred antiretroviral therapy for HIV on survival.N Engl J Med2009; 360: 1815–1826.
8.
LimaV.D., ReuterA., HarriganP.R.Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes.AIDS2015; 29: 1871–1882.
9.
AnglemyerA., RutherfordG.W., EasterbrookP.J.Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: a systematic review.AIDS2014; 28Suppl 2: S105–S118.
10.
GranichR.M., GilksC.F., DyeC., De CockK.M., WilliamsB.G.Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.Lancet2009; 373: 48–57.
11.
Starting antiretroviral treatment early improves outcomes for HIV-infected individuals: National Institutes of Health; 2015. (Updated 27 May 2015. Accessed 1 June 2015.) Available from http://www.nih.gov/news/health/may2015/niaid-27.htm.
12.
INSIGHT START Study Group, Lundgren JD, Babiker AG, et al.Initiation of antiretroviral therapy in early asymptomatic HIV infection.N Engl J Med2015; 373: 795–807.
MontanerJ.S., LimaV.D., BarriosR.Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.Lancet2010; 376: 532–539.
15.
CohenM.S., ChenY.Q., McCauleyM.Prevention of HIV-1 infection with early antiretroviral therapy.N Engl J Med2011; 365: 493–505.
16.
VlahovD., GalaiN., SafaeianM.Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection.Am J Epidemiol2005; 161: 999–1012.
17.
McGowanC.C., WeinsteinD.D., SamenowC.P.Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts.PLoS One2011; 6: e18462.
18.
CelentanoD.D., GalaiN., SethiA.K.Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.AIDS2001; 15: 1707–1715.
19.
SoodN., WagnerZ., JaycocksA., DraboE., VardavasR.Test-and-treat in Los Angeles: a mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County.Clin Infect Dis2013; 56: 1789–1796.
20.
StrathdeeS.A., PalepuA., CornelisseP.G.Barriers to use of free antiretroviral therapy in injection drug users.JAMA1998; 280: 547–549.
21.
HoggR.S., HeathK.V., StrathdeeS.A., MontanerJ.S., O'ShaughnessyM.V., SchechterM.T.HIV/AIDS mortality in Canada: evidence of gender, regional and local area differentials.AIDS1996; 10: 889–894.
22.
SchneiderE., WhitmoreS., GlynnK.M.Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years–United States, 2008.MMWR Recomm Rep2008; 57 (RR-10): 1–12.
23.
SangsariS., MilloyM.J., IbrahimA.Physician experience and rates of plasma HIV-1 RNA suppression among illicit drug users: an observational study.BMC Infect Dis2012; 12: 22.
24.
LimaV., FernandesK., RachlisB., DruytsE., MontanerJ., HoggR.Migration adversely affects antiretroviral adherence in a population-based cohort of HIV/AIDS patients.Soc Sci Med2009; 68: 1044–1049.
25.
MilloyM.J., KerrT., BuxtonJ.Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users.J Infect Dis2011; 203: 1215–1221.
26.
MaldonadoG., GreenlandS.Simulation study of confounder-selection strategies.Am J Epidemiol1993; 138: 923–936.
27.
KleinbaumD.G., KleinM.Survival analysis: a self-learning text.New York: Springer; 2005.
LucasG.M., CheeverL.W., ChaissonR.E., MooreR.D.Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.J Acquir Immune Defic Syndr2001; 27: 251–259.
30.
HsuL.C., TruongH.M., VittinghoffE., ZhiQ., ScheerS., SchwarczS.Trends in early initiation of antiretroviral therapy and characteristics of persons with HIV initiating therapy in San Francisco, 2007-2011.J Infect Dis2014; 209: 1310–1314.
31.
MehtaS.H., KirkG.D., AstemborskiJ., GalaiN., CelentanoD.D.Temporal trends in highly active antiretroviral therapy initiation among injection drug users in Baltimore, Maryland, 1996-2008.Clin Infect Dis2010; 50: 1664–1671.
32.
CesconA.M., CooperC., ChanK.Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.HIV Med2011; 12: 352–360.
33.
WoodE., KerrT., TyndallM.W., MontanerJ.S.A review of barriers and facilitators of HIV treatment among injection drug users.AIDS2008; 22: 1247–1256.
34.
WeberR., HuberM., RickenbachM.Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study.HIV Med2009; 10: 407–416.
35.
KnowltonA., ArnstenJ., EldredL.Individual, interpersonal, and structural correlates of effective HAART use among urban active injection drug users.J Acquir Immune Defic Syndr2006; 41: 486–492.
36.
PenceB.W., MillerW.C., GaynesB.N., EronJ.J.Jr.. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy.J Acquir Immune Defic Syndr2007; 44: 159–166.
37.
MehtaS.H., LucasG., AstemborskiJ., KirkG.D., VlahovD., GalaiN.Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users.AIDS Care2007; 19: 637–645.
38.
RileyE.D., MooreK.L., HaberS., NeilandsT.B., CohenJ., KralA.H.Population-level effects of uninterrupted health insurance on services use among HIV-positive unstably housed adults.AIDS Care2011; 23: 822–830.
